FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.
/ 220 items
#andre↓
Jana Partners Raises Stake in Alkami to Over 10% and Intensifies Sale Push
The activist investor is pushing for leadership changes and a broad sale process.
Super Micro Offices Raided in Taiwan as Chip Smuggling Probe Widens
Taiwan raided Super Micro offices on June 29, 2026, as part of an expanding investigation into alleged smuggling of Nvidia AI chips to China.
Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
Forager Raises Take-Private Offer for Repay Holdings to $5.25 Per Share
Repay shares jumped 22% after Forager raised its buyout offer to $5.25 cash, but the deal is still not final.
Strategy Announces $2 Billion Buyback Program and Plans to Sell Bitcoin to Restore Investor Confidence
After an 80% stock drop, Strategy will repurchase $2B in shares and may sell part of its Bitcoin holdings. Company raises Stretch dividend to 12% starting July 1.